Combined treatment with a PKC inhibitor and all-trans-retinoic acid (ATRA) reduced the growth, self-renewal, and frequency of cancer stem cells (CSCs) in a retinoic acid receptor (RAR) signaling-dependent manner. The gene discussed is PRRT2; the disease is cancer.